Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
TLK286 with a single agent or a combined chemotherapeutic regimen has shown safe antitumor activity and clinical benefit in phases II (81) and III (83) clinical trials for treating patients with ovarian and breast cancers (84)
Citations Citations to this article as recorded by Why are we still missing the pain
Patients who depend on insurance to make these drugs affordable will find Hims model financially unrealistic
No conversion cost
US$ 23.21
US$ 21.09
US$ 22.98
US$ 21.20
US$ 27.35
/assets/images/provider/photos/2657131.jpg)
US$ 29.51
US$ 29.95
